Boston Scientific Gestione

Gestione criteri di controllo 3/4

Boston Scientific Il CEO è Mike Mahoney, nominato in Oct2011, e ha un mandato di 13.08 anni. la retribuzione annua totale è $ 18.72M, composta da 7.5% di stipendio e 92.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di € 147.72M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.6 anni e 8.3 anni.

Informazioni chiave

Mike Mahoney

Amministratore delegato

US$18.7m

Compenso totale

Percentuale dello stipendio del CEO	7.5%
Mandato del CEO	13.1yrs
Proprietà del CEO	0.1%
Durata media del management	8.6yrs
Durata media del Consiglio di amministrazione	8.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mike Mahoney rispetto agli utili di Boston Scientific?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$19m	US$1m	US$2b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$861m
Mar 31 2023	n/a	n/a	US$846m
Dec 31 2022	US$17m	US$1m	US$642m
Sep 30 2022	n/a	n/a	US$596m
Jun 30 2022	n/a	n/a	US$828m
Mar 31 2022	n/a	n/a	US$754m
Dec 31 2021	US$16m	US$1m	US$985m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$526m
Mar 31 2021	n/a	n/a	US$201m
Dec 31 2020	US$14m	US$667k	-US$115m
Sep 30 2020	n/a	n/a	US$4b
Jun 30 2020	n/a	n/a	US$4b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$16m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$14m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$670m
Jun 30 2018	n/a	n/a	US$521m
Mar 31 2018	n/a	n/a	US$112m
Dec 31 2017	US$13m	US$1m	US$104m

Compensazione vs Mercato: La retribuzione totale di Mike ($USD 18.72M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 4.87M ).

Compensazione vs guadagni: La retribuzione di Mike è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Mike Mahoney (59 yo)

13.1yrs

Mandato

US$18,723,735

Compensazione

Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Mahoney	Chairman	13.1yrs	US$18.72m	0.12% € 147.7m
Daniel Brennan	Executive VP & CFO	10.8yrs	US$5.83m	0.015% € 19.1m
Joseph Fitzgerald	Executive VP & Group President of Cardiology	14.8yrs	US$5.59m	0.011% € 14.1m
Jeffrey Mirviss	Executive VP & President of Peripheral Interventions	11.8yrs	US$3.78m	0.0019% € 2.4m
Arthur Crosswell Butcher	Executive VP and Group President of MedSurg & Asia Pacific	8.3yrs	US$4.27m	0.0016% € 2.1m
John Sorenson	Executive Vice President of Global Operations	2.5yrs	Nessun dato	0.0025% € 3.2m
Emily Woodworth	Senior VP	less than a year	Nessun dato	0.00026% € 327.1k
Jodi Eddy	Senior VP and Chief Information & Digital Officer	8.9yrs	Nessun dato	Nessun dato
Jonathan Monson	Senior VP of Investor Relations	less than a year	Nessun dato	0.0026% € 3.2m
Vance Brown	Senior VP	3.4yrs	Nessun dato	0.0023% € 2.9m
Mary Moynihan	Senior VP of Market Access & Chief Marketing Officer	3.5yrs	Nessun dato	Nessun dato
Wendy Carruthers	Executive Vice President of Human Resources	11.9yrs	Nessun dato	0.0022% € 2.7m

8.6yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di BSX è esperto e expertise (durata media dell'incarico 8.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Mahoney	Chairman	12yrs	US$18.72m	0.12% € 147.7m
Edward Ludwig	Lead Independent Director	10.7yrs	US$360.00k	0.0030% € 3.8m
Ellen Zane	Independent Director	8.6yrs	US$335.00k	0.0033% € 4.1m
Yoshiaki Fujimori	Independent Director	8.3yrs	US$320.00k	0.00020% € 251.6k
David Wichmann	Independent Director	3.4yrs	US$338.75k	0.0027% € 3.4m
Cheryl Pegus	Director	less than a year	Nessun dato	Nessun dato
David Habiger	Director	less than a year	Nessun dato	0.00024% € 302.0k
Charles Dockendorff	Independent Director	9.6yrs	US$326.25k	0.0043% € 5.4m
John Sununu	Independent Director	15.6yrs	US$340.00k	0.0036% € 4.5m
Jessica Mega	Independent Director	1.4yrs	US$233.23k	0.00042% € 528.4k
Susan Morano	Independent Director	1.4yrs	US$233.23k	0.00027% € 339.7k

8.3yrs

Durata media

60.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BSX sono considerati esperti (durata media dell'incarico 8.3 anni).

Boston Scientific Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Boston Scientific Corporation Elects David Habiger to Board of Directors

Boston Scientific Corporation Appoints Cheryl Pegus to its Board of Directors

Boston Scientific Corporation, Annual General Meeting, May 02, 2024

Boston Scientific Corporation Announces Executive Changes, Effective March 1, 2024

Nelda J. Connors and David J. Roux Not to Stand for Re-Election as Members of the Board of Directors of Boston Scientific Corporation

Insider recently sold €2.5m worth of stock

Recent updates

Boston Scientific Corporation Announces Positive Three-Year Primary Endpoint Results from the OPTION Global Clinical Trial of the Watchman FLX

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Cortex, Inc. from Ajax Health.

Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Cortex EP from Ajax Health.

Third quarter 2024 earnings released: EPS: US$0.32 (vs US$0.34 in 3Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Boston Scientific Corporation Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System

Boston Scientific Corporation to Report Q3, 2024 Results on Oct 23, 2024

Boston Scientific Corporation Receives Japanese Regulatory Approval for the Farapulse™ Pulsed Field Ablation System

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Silk Road Medical, Inc (NasdaqGS:SILK) from a group of shareholders.

Boston Scientific Corporation Elects David Habiger to Board of Directors

Second quarter 2024 earnings released: EPS: US$0.22 (vs US$0.18 in 2Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Third Quarter and Full Year of Fiscal Year 2024

Boston Scientific Corporation to Report Q2, 2024 Results on Jul 24, 2024

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Boston Scientific Corporation Appoints Cheryl Pegus to its Board of Directors

First quarter 2024 earnings released: EPS: US$0.34 (vs US$0.21 in 1Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Boston Scientific Corporation to Report Q1, 2024 Results on Apr 24, 2024

New minor risk - Shareholder dilution

Boston Scientific Corporation, Annual General Meeting, May 02, 2024

Full year 2023 earnings released: EPS: US$1.08 (vs US$0.45 in FY 2022)

Boston Scientific Corporation Announces Executive Changes, Effective March 1, 2024

Boston Scientific Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2024

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Boston Scientific Corporation to Report Q4, 2023 Results on Jan 31, 2024

Boston Scientific Corporation Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

Nelda J. Connors and David J. Roux Not to Stand for Re-Election as Members of the Board of Directors of Boston Scientific Corporation

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Relievant Medsystems, Inc.

Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.12 in 3Q 2022)

Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal AGENT IDE Clinical Trial of the AGENT™ Drug-Coated Balloon

Boston Scientific Corporation Provides Earnings Guidance for the Full Year 2023

Boston Scientific Corporation Announces FDA Approval for the Latest-Generation watchMAN FLX Pro Left Atrial Appendage Closure Device

Boston Scientific Corporation to Report Q3, 2023 Results on Oct 26, 2023

Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal Advanced Clinical Trial of the FARAPULSE™ Pulsed Field Ablation System

Boston Scientific Corporation Receives FDA Approval for the POLARx™ Cryoablation System

New minor risk - Earnings quality

New minor risk - Shareholder dilution

Boston Scientific Corporation (NYSE:BSX) agreed to acquire EV Business and B Braun of Aesculap AG for €47 million.

Second quarter 2023 earnings released: EPS: US$0.18 (vs US$0.17 in 2Q 2022)

Boston Scientific Corporation to Report Q2, 2023 Results on Jul 27, 2023

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of an additional stake in M.I.TECH Co.,Ltd (KOSDAQ:A179290) from Synergy Innovation Co., Ltd. (KOSDAQ:A048870)

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Insider recently sold €2.5m worth of stock

First quarter 2023 earnings released: EPS: US$0.21 (vs US$0.068 in 1Q 2022)

Insider recently sold €537k worth of stock

Boston Scientific Corporation Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System

Full year 2022 earnings released: EPS: US$0.45 (vs US$0.69 in FY 2021)

Boston Scientific Corporation Provides Earnings Guidance for First Quarter of 2023 and Full Year 2023

Boston Scientific Corporation, Annual General Meeting, May 04, 2023

Boston Scientific Corporation to Report Q4, 2022 Results on Feb 01, 2023

Independent Director recently sold €783k worth of stock

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation Announces the First Results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) Study

Insider recently sold €616k worth of stock

Insufficient new directors

Boston Scientific Corporation announced that it expects to receive funding from BeWeld Medical Ltd.

Boston Scientific Corporation Announces Impairment Results for the Three Months Ended September 30, 2022

Third quarter 2022 earnings released: EPS: US$0.12 (vs US$0.28 in 3Q 2021)

Now 20% undervalued

Boston Scientific Corporation to Report Q3, 2022 Results on Oct 26, 2022

Now 21% undervalued

Boston Scientific Announces Results from the PROTECTED TAVR Clinical Trial

Boston Scientific Corporation Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option